Mankind Pharma tie-ups with Lepra Society to establish CDCC Centres to screen 80,000 individuals

The CDCCs are strategically positioned in regions identified as high-impact areas

Qure.ai adds new FDA breakthrough device status for qSpot-TB

4 FDA clearances & 61 EU MDR CE tags achieved for AI in 18 months

Dr. Jitendra Singh launches multi-disciplinary post-doctoral courses in Bio-Sciences

1,000 Ph.D. students will be enrolled in the next five years to drive innovation in the critical healthcare sector

Mandaviya inaugurates 24 health infrastructure facilities across AIIMS

Delivers keynote address at the 4th convocation of AIIMS Jodhpur

Industry’s reaction to Union Budget 2024-25

Indian Pharma Post brings together the views of industry leaders on the Interim Union Budget 2024-25 announcement and its impact on the industry

Lupin Digital Health introduces digital therapeutics certificate for Cardiologists in India in collaboration with ACC

Ascletis announces dosing of the first patient in Phase III clinical trial of ASC40

This Phase III clinical trial is a randomized, double-blind, placebo-controlled, multicenter clinical trial in China to evaluate the safety and efficacy of ASC40

Glenmark, Ichnos Sciences form ‘Ichnos Glenmark Innovation’ for new drug discovery in cancer treatment

This alliance brings together drug innovation capabilities of Glenmark and Ichnos to develop cutting-edge therapies for the treatment of hematological malignancies and solid tumors

Merck’s Keytruda reduced the risk of death by 38% for patients with RCC

Keynote -564 is the first Phase 3 trial to demonstrate superior overall survival (OS) with adjuvant therapy compared to placebo in patients with RCC

Syngene Q3 FY 24 PAT up 4% to Rs 115 Cr

For 9 months period ended December 2023, the company’s PAT up 16% to Rs 330 crores (before exceptional items)